HACKENSACK, N.J.--(BUSINESS WIRE)--Amorcyte, Inc. (Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001 – an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI).
